QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
OTCMKTS:PTIX

Protagenic Therapeutics - PTIX Stock Forecast, Price & News

$0.68
+0.08 (+13.38%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.58
$0.71
50-Day Range
$0.58
$0.83
52-Week Range
$0.56
$2.35
Volume
141,052 shs
Average Volume
65,978 shs
Market Capitalization
$11.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Protagenic Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
490.2% Upside
$4.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$16,330 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

PTIX stock logo

About Protagenic Therapeutics (OTCMKTS:PTIX) Stock

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Receive PTIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTIX Stock News Headlines

Protagenic Therapeutics, Inc. (PTIX)
Protagenic Therapeutics Inc.
Carlsmed Raises $2.5M to Improve Complex Spine Surgery
See More Headlines
Receive PTIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTIX Company Calendar

Last Earnings
11/16/2021
Today
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PTIX
Employees
1
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+490.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.59 per share

Miscellaneous

Free Float
9,507,000
Market Cap
$11.71 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 69)
    Co-Founder & Exec. Chairman
  • Dr. Alexander Kenneth Arrow C.F.A. (Age 51)
    M.D., CFO & Sec.
    Comp: $136.54k
  • Dr. Andrew Slee (Age 72)
    Chief Operating Officer
  • Dr. Robert Benjamin Stein M.D. (Age 71)
    Ph.D., Chief Medical Officer & Director
  • Dr. David A. Lovejoy
    Chief Scientific Officer, Scientific Founder & Scientific Advisor













PTIX Stock - Frequently Asked Questions

Should I buy or sell Protagenic Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagenic Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTIX shares.
View PTIX analyst ratings
or view top-rated stocks.

What is Protagenic Therapeutics' stock price forecast for 2022?

1 Wall Street analysts have issued 12 month target prices for Protagenic Therapeutics' stock. Their PTIX share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 490.2% from the stock's current price.
View analysts price targets for PTIX
or view top-rated stocks among Wall Street analysts.

How have PTIX shares performed in 2022?

Protagenic Therapeutics' stock was trading at $1.3850 at the start of the year. Since then, PTIX stock has decreased by 51.1% and is now trading at $0.6777.
View the best growth stocks for 2022 here
.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) issued its quarterly earnings data on Tuesday, November, 16th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03.

What other stocks do shareholders of Protagenic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), Akero Therapeutics (AKRO), Athersys (ATHX), AVEO Pharmaceuticals (AVEO), CymaBay Therapeutics (CBAY), Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX).

What is Protagenic Therapeutics' stock symbol?

Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."

Who are Protagenic Therapeutics' major shareholders?

Protagenic Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.29%).
View institutional ownership trends
.

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagenic Therapeutics' stock price today?

One share of PTIX stock can currently be purchased for approximately $0.68.

How much money does Protagenic Therapeutics make?

Protagenic Therapeutics (OTCMKTS:PTIX) has a market capitalization of $11.71 million.

How can I contact Protagenic Therapeutics?

Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The official website for the company is www.protagenic.com. The biotechnology company can be reached via phone at (212) 994-8200, via email at alex.arrow@protagenic.com, or via fax at 603-761-6223.

This page (OTCMKTS:PTIX) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.